All In Biotech

Drug Trial Radar · NCT05428943

OPT101 in Type 1 Diabetes Patients

A Phase 1b Study of OPT101 in Patients With Type 1 Diabetes

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Sep 27, 2022

Primary completion

Feb 21, 2024

Study completion Feb 21, 2024

Sponsor

Lead sponsor
Op-T LLCIndustry
Sponsor type
Industry
First posted
Jun 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • OPT101Drug

    15-mer peptide derived from the sequence of mouse CD154.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment-related AE's as Assessed by CTCAE v4.0Time frame: 42 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Diablo Clinical Research Center

    Walnut Creek, California

  • Rainier Clinical Research Center

    Renton, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.